Your browser doesn't support javascript.
loading
Glioneuronal tumor with ATRX alteration, kinase fusion and anaplastic features (GTAKA): a molecularly distinct brain tumor type with recurrent NTRK gene fusions.
Bogumil, Henri; Sill, Martin; Schrimpf, Daniel; Ismer, Britta; Blume, Christina; Rahmanzade, Ramin; Hinz, Felix; Cherkezov, Asan; Banan, Rouzbeh; Friedel, Dennis; Reuss, David E; Selt, Florian; Ecker, Jonas; Milde, Till; Pajtler, Kristian W; Schittenhelm, Jens; Hench, Jürgen; Frank, Stephan; Boldt, Henning B; Kristensen, Bjarne Winther; Scheie, David; Melchior, Linea C; Olesen, Viola; Sehested, Astrid; Boué, Daniel R; Abdullaev, Zied; Satgunaseelan, Laveniya; Kurth, Ina; Seidlitz, Annekatrin; White, Christine L; Ng, Ho-Keung; Shi, Zhi-Feng; Haberler, Christine; Deckert, Martina; Timmer, Marco; Goldbrunner, Roland; Tauziède-Espariat, Arnault; Varlet, Pascale; Brandner, Sebastian; Alexandrescu, Sanda; Snuderl, Matija; Aldape, Kenneth; Korshunov, Andrey; Witt, Olaf; Herold-Mende, Christel; Unterberg, Andreas; Wick, Wolfgang; Pfister, Stefan M; von Deimling, Andreas; Jones, David T W.
Afiliación
  • Bogumil H; Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
  • Sill M; Clinical Cooperation Unit Neuropathology, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Schrimpf D; Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
  • Ismer B; Division of Pediatric Neurooncology, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Blume C; Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
  • Rahmanzade R; Clinical Cooperation Unit Neuropathology, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Hinz F; Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
  • Cherkezov A; Division of Pediatric Glioma Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Banan R; Faculty of Biosciences, Heidelberg University, Heidelberg, Germany.
  • Friedel D; Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
  • Reuss DE; Clinical Cooperation Unit Neuropathology, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Selt F; Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
  • Ecker J; Clinical Cooperation Unit Neuropathology, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Milde T; Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
  • Pajtler KW; Clinical Cooperation Unit Neuropathology, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Schittenhelm J; Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
  • Hench J; Clinical Cooperation Unit Neuropathology, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Frank S; Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
  • Boldt HB; Clinical Cooperation Unit Neuropathology, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Kristensen BW; Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
  • Scheie D; Clinical Cooperation Unit Neuropathology, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Melchior LC; Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
  • Olesen V; Clinical Cooperation Unit Neuropathology, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Sehested A; Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
  • Boué DR; Clinical Cooperation Unit Pediatric Oncology, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Abdullaev Z; Department of Pediatric Oncology, Hematology, Immunology and Pulmonology, University Hospital Heidelberg, Heidelberg, Germany.
  • Satgunaseelan L; National Center for Tumor Diseases (NCT), Heidelberg, Germany.
  • Kurth I; Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
  • Seidlitz A; Clinical Cooperation Unit Pediatric Oncology, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • White CL; Department of Pediatric Oncology, Hematology, Immunology and Pulmonology, University Hospital Heidelberg, Heidelberg, Germany.
  • Ng HK; National Center for Tumor Diseases (NCT), Heidelberg, Germany.
  • Shi ZF; Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
  • Haberler C; Clinical Cooperation Unit Pediatric Oncology, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Deckert M; Department of Pediatric Oncology, Hematology, Immunology and Pulmonology, University Hospital Heidelberg, Heidelberg, Germany.
  • Timmer M; National Center for Tumor Diseases (NCT), Heidelberg, Germany.
  • Goldbrunner R; Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
  • Tauziède-Espariat A; Division of Pediatric Neurooncology, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Varlet P; Department of Pediatric Oncology, Hematology, Immunology and Pulmonology, University Hospital Heidelberg, Heidelberg, Germany.
  • Brandner S; Center for Neuro-Oncology, Comprehensive Cancer Center Tübingen-Stuttgart, University Hospital Tübingen, Eberhard-Karls-University Tübingen, Tübingen, Germany.
  • Alexandrescu S; German Cancer Consortium (DKTK), DKFZ Partner Site Tübingen, Tübingen, Germany.
  • Snuderl M; Department of Neuropathology, University Hospital Tübingen, Eberhard-Karls-University Tübingen, Tübingen, Germany.
  • Aldape K; Division of Neuropathology, Institute for Pathology, University Hospital Basel, Basel, Switzerland.
  • Korshunov A; Division of Neuropathology, Institute for Pathology, University Hospital Basel, Basel, Switzerland.
  • Witt O; Department of Pathology, Odense University Hospital, Odense, Denmark.
  • Herold-Mende C; Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
  • Unterberg A; Department of Pathology, Odense University Hospital, Odense, Denmark.
  • Wick W; Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
  • Pfister SM; Department of Pathology, The Bartholin Institute, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
  • von Deimling A; Department of Clinical Medicine and Biotech Research & Innovation Centre (BRIC), University of Copenhagen, Copenhagen, Denmark.
  • Jones DTW; Department of Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Acta Neuropathol ; 145(5): 667-680, 2023 05.
Article en En | MEDLINE | ID: mdl-36933012
ABSTRACT
Glioneuronal tumors are a heterogenous group of CNS neoplasms that can be challenging to accurately diagnose. Molecular methods are highly useful in classifying these tumors-distinguishing precise classes from their histological mimics and identifying previously unrecognized types of tumors. Using an unsupervised visualization approach of DNA methylation data, we identified a novel group of tumors (n = 20) that formed a cluster separate from all established CNS tumor types. Molecular analyses revealed ATRX alterations (in 16/16 cases by DNA sequencing and/or immunohistochemistry) as well as potentially targetable gene fusions involving receptor tyrosine-kinases (RTK; mostly NTRK1-3) in all of these tumors (16/16; 100%). In addition, copy number profiling showed homozygous deletions of CDKN2A/B in 55% of cases. Histological and immunohistochemical investigations revealed glioneuronal tumors with isomorphic, round and often condensed nuclei, perinuclear clearing, high mitotic activity and microvascular proliferation. Tumors were mainly located supratentorially (84%) and occurred in patients with a median age of 19 years. Survival data were limited (n = 18) but point towards a more aggressive biology as compared to other glioneuronal tumors (median progression-free survival 12.5 months). Given their molecular characteristics in addition to anaplastic features, we suggest the term glioneuronal tumor with ATRX alteration, kinase fusion and anaplastic features (GTAKA) to describe these tumors. In summary, our findings highlight a novel type of glioneuronal tumor driven by different RTK fusions accompanied by recurrent alterations in ATRX and homozygous deletions of CDKN2A/B. Targeted approaches such as NTRK inhibition might represent a therapeutic option for patients suffering from these tumors.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Encefálicas / Neoplasias del Sistema Nervioso Central / Neoplasias Neuroepiteliales Tipo de estudio: Prognostic_studies Límite: Adult / Humans Idioma: En Revista: Acta Neuropathol Año: 2023 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Encefálicas / Neoplasias del Sistema Nervioso Central / Neoplasias Neuroepiteliales Tipo de estudio: Prognostic_studies Límite: Adult / Humans Idioma: En Revista: Acta Neuropathol Año: 2023 Tipo del documento: Article País de afiliación: Alemania